NCT05460364 - A Study to Evaluate the Pharmacokinetic Interaction and Safety Between BR1018-1 and BR1018-2 in Healthy Adult Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 4, 2022

Primary Completion Date

October 17, 2022

Study Completion Date

October 17, 2022

Conditions

HypertensionHyperlipidemia (E.G., Hypercholesterolemia)

Interventions

DRUG

BR1018-1

"Treatment group A : One tablet of BR1018-1 administered alone once daily for 9 days.~Treatment group C : One tablet each of BR1018-1 and BR1018-2 administered in combination once daily for 9 days."

DRUG

BR1018-2

"Treatment group B : One tablet of BR1018-2 administered alone once daily for 9 days.~Treatment group C : One tablet each of BR1018-1 and BR1018-2 administered in combination once daily for 9 days."

Trial Locations (1)

Unknown

Inha University Hospital, Incheon